千金药业收购2家子公司股权 加速旗下资源整合

Group 1 - Zhuzhou Qianjin Pharmaceutical Co., Ltd. received approval from the China Securities Regulatory Commission to acquire 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] - The transaction aims to enhance the control of Zhuzhou Guotou over the listed company, increasing its shareholding from 28.76% to 34.94%, which supports stable governance and control of the listed company [1] - The effects of policies such as the "Eight Articles for the Sci-Tech Innovation Board" and "Six Articles for Mergers and Acquisitions" are becoming evident, with 27 merger and reorganization projects accepted and 15 approved by the review committee since 2025, surpassing last year's total [1] Group 2 - The Shanghai Stock Exchange is focused on improving the efficiency of reorganization reviews, with several innovative and exemplary merger and reorganization cases being implemented, such as the mergers involving Silyus and Sanyou Medical [2] - Notable cases include the acquisition of Chiplink Integrated by Chiplink Yuezhou, the largest merger project in A-shares involving China Shipbuilding and China Shipbuilding Heavy Industry, and cross-industry mergers by Songfa Co. and cross-border mergers by Zhizheng Co. [2]